CY1124173T1 - Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες - Google Patents

Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες

Info

Publication number
CY1124173T1
CY1124173T1 CY20211100444T CY211100444T CY1124173T1 CY 1124173 T1 CY1124173 T1 CY 1124173T1 CY 20211100444 T CY20211100444 T CY 20211100444T CY 211100444 T CY211100444 T CY 211100444T CY 1124173 T1 CY1124173 T1 CY 1124173T1
Authority
CY
Cyprus
Prior art keywords
methods
therapy
compositions
aminopurine compounds
compounds
Prior art date
Application number
CY20211100444T
Other languages
English (en)
Inventor
Matthew Alexander
Sogole Bahmanyar
John Fredrerick Boylan
Joshua Hansen
Dehua Huang
Robert Hubbard
Brandon Jeffy
Jim Leisten
Mehran Moghaddam
Raj K. Raheja
Heather Raymon
Kimberly Schwarz
Marianne Sloss
Eduardo Torres
Tam Minh Tran
Shuichan Xu
Jingjing Zhao
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of CY1124173T1 publication Critical patent/CY1124173T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Στο παρόν παρέχονται Ενώσεις Αμινοπουρίνης που έχουν τις ακόλουθες δομές, όπου τα R1, R2 και R3 είναι όπως ορίζονται στο παρόν, σύνθεση που περιλαμβάνει μία αποτελεσματική ποσότητα μιας Ένωσης Αμινοπουρίνης και μέθοδοι για τη θεραπεία ή την πρόληψη ενός καρκίνου, παραδείγματος χάριν μελανώματος. Παρέχονται στο παρόν ενώσεις που έχουν τον ακόλουθο τύπο (Ι) και φαρμακευτικά αποδεκτά άλατα, ταυτομερή, ισοτοπόλογα και στερεοϊσομερή αυτών, όπου τα R1, R2 και R3 είναι όπως ορίζονται στο παρόν.
CY20211100444T 2014-10-06 2021-05-24 Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες CY1124173T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
PCT/US2015/053941 WO2016057370A1 (en) 2014-10-06 2015-10-05 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
CY1124173T1 true CY1124173T1 (el) 2022-05-27

Family

ID=55632334

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100444T CY1124173T1 (el) 2014-10-06 2021-05-24 Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες

Country Status (28)

Country Link
US (8) US9512124B2 (el)
EP (2) EP3822274B1 (el)
JP (4) JP6884701B2 (el)
KR (2) KR20230035424A (el)
CN (2) CN113248506A (el)
AR (1) AR102171A1 (el)
AU (2) AU2015328414B2 (el)
CA (1) CA2963639C (el)
CL (1) CL2017000820A1 (el)
CO (1) CO2017003838A2 (el)
CY (1) CY1124173T1 (el)
DK (1) DK3204386T3 (el)
EA (1) EA201790779A1 (el)
EC (1) ECSP17026210A (el)
ES (1) ES2871142T3 (el)
HR (1) HRP20210656T1 (el)
HU (1) HUE054694T2 (el)
IL (2) IL251566B (el)
LT (1) LT3204386T (el)
MX (2) MX2017004600A (el)
NZ (2) NZ730753A (el)
PL (1) PL3204386T3 (el)
PT (1) PT3204386T (el)
RS (1) RS61884B1 (el)
SG (2) SG11201702759XA (el)
SI (1) SI3204386T1 (el)
TW (1) TW201629063A (el)
WO (1) WO2016057370A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3204386T (pt) * 2014-10-06 2021-05-31 Signal Pharm Llc Compostos de aminopurina substituída, suas composições e métodos de tratamento com os mesmos
JP6903577B2 (ja) 2014-12-16 2021-07-14 シグナル ファーマシューティカルズ，エルエルシー 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR102630010B1 (ko) 2015-03-18 2024-01-25 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 트리시클릭 헤테로시클릭 화합물
ES2803650T3 (es) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Compuestos heterocíclicos útiles como inhibidores de TNF
MX2017011434A (es) 2015-03-18 2018-01-25 Squibb Bristol Myers Co Compuestos heterociclicos triciclicos sustituidos.
JP6805232B2 (ja) 2015-07-24 2020-12-23 セルジーン コーポレイション （１ｒ，２ｒ，５ｒ）−５−アミノ−２−メチルシクロヘキサノール塩酸塩の合成方法及びそれに有用な中間体
CA2994703A1 (en) 2015-08-03 2017-02-09 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
CA3019105A1 (en) * 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Solid forms of (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
MX2018011992A (es) * 2016-04-01 2019-01-24 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
ES2926149T3 (es) * 2016-06-02 2022-10-24 Celgene Corp Agentes antipalúdicos animales y humanos
TW201802093A (zh) 2016-06-02 2018-01-16 西建公司 動物及人類抗錐蟲及抗利什曼原蟲藥劑
US10543214B2 (en) 2017-10-04 2020-01-28 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CN111417634A (zh) * 2017-10-04 2020-07-14 细胞基因公司 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CN102382113B (zh) 2006-10-27 2016-04-06 西格诺药品有限公司 包含用于治疗疾病或紊乱的化合物的固体形式，其组合物，及其用途
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
WO2014172616A2 (en) 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
PT3204386T (pt) * 2014-10-06 2021-05-31 Signal Pharm Llc Compostos de aminopurina substituída, suas composições e métodos de tratamento com os mesmos
CA3019105A1 (en) 2016-04-01 2017-10-05 Signal Pharmaceuticals, Llc Solid forms of (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Also Published As

Publication number Publication date
CA2963639C (en) 2023-07-04
IL251566B (en) 2020-09-30
US11590139B2 (en) 2023-02-28
US10940152B2 (en) 2021-03-09
KR20230035424A (ko) 2023-03-13
CA2963639A1 (en) 2016-04-14
US20230158035A1 (en) 2023-05-25
JP2022033858A (ja) 2022-03-02
WO2016057370A1 (en) 2016-04-14
EA201790779A1 (ru) 2017-09-29
US20170296546A1 (en) 2017-10-19
EP3822274A1 (en) 2021-05-19
DK3204386T3 (da) 2021-05-25
EP3204386A1 (en) 2017-08-16
JP2017530199A (ja) 2017-10-12
JP6884701B2 (ja) 2021-06-09
IL251566A0 (en) 2017-05-29
JP2020033352A (ja) 2020-03-05
US20160096841A1 (en) 2016-04-07
PL3204386T3 (pl) 2021-09-20
SI3204386T1 (sl) 2021-08-31
CN113248506A (zh) 2021-08-13
KR20170063740A (ko) 2017-06-08
IL277069B (en) 2022-05-01
EP3204386A4 (en) 2018-04-18
MX2021014531A (es) 2022-01-06
TW201629063A (zh) 2016-08-16
ECSP17026210A (es) 2017-05-31
IL277069A (en) 2020-10-29
US20200237768A1 (en) 2020-07-30
AU2015328414A1 (en) 2017-04-27
US20170042902A1 (en) 2017-02-16
KR102504849B1 (ko) 2023-03-02
NZ730753A (en) 2024-02-23
CN107001372A (zh) 2017-08-01
US9737541B2 (en) 2017-08-22
CL2017000820A1 (es) 2017-12-15
US9512124B2 (en) 2016-12-06
EP3204386B1 (en) 2021-03-03
US10398700B2 (en) 2019-09-03
EP3822274B1 (en) 2024-03-06
LT3204386T (lt) 2021-07-12
JP6987823B2 (ja) 2022-01-05
PT3204386T (pt) 2021-05-31
US10646493B2 (en) 2020-05-12
AU2020201486A1 (en) 2020-03-19
ES2871142T3 (es) 2021-10-28
AR102171A1 (es) 2017-02-08
MX2017004600A (es) 2017-06-30
SG10202009598VA (en) 2020-10-29
HUE054694T2 (hu) 2021-09-28
NZ767954A (en) 2024-02-23
US20210128565A1 (en) 2021-05-06
US20190091230A1 (en) 2019-03-28
US10149849B2 (en) 2018-12-11
JP7196270B2 (ja) 2022-12-26
AU2020201486B2 (en) 2021-07-08
HRP20210656T1 (hr) 2021-07-23
US20190336507A1 (en) 2019-11-07
CN107001372B (zh) 2021-04-27
JP2023027269A (ja) 2023-03-01
AU2015328414B2 (en) 2020-03-19
CO2017003838A2 (es) 2017-07-11
RS61884B1 (sr) 2021-06-30
BR112017006998A2 (pt) 2018-01-16
SG11201702759XA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1122340T1 (el) Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1121901T1 (el) Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123475T1 (el) Αναστολεις της ειδικης για λυσινη απομεθυλασης-1
CY1123451T1 (el) Αγωνιστες τριαζολης του υποδοχεα αρj
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
CL2021000175A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина